ERAS INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Erasca, Inc. faces a securities class action lawsuit alleging that the company and its executives made false statements about its lead drug candidate ERAS-0015. The lawsuit claims preclinical data was based on improper comparisons and lacked reasonable basis. On April 27, 2026, Erasca disclosed a patent infringement assertion from Revolution Medicines and reported a patient death in Phase I trials, causing the stock to plummet nearly 59% over two trading days. Investors with substantial losses can seek appointment as lead plaintiff by August 10, 2026.